Harnessing T Follicular Helper Cell Responses for HIV Vaccine Development

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
AIDS 2 infectiousdiseases
diphtheria 1 infectiousdiseases
hepatitis C 1 infectiousdiseases
yellow fever 1 infectiousdiseases
tetanus 1 infectiousdiseases
hepatitis A 1 infectiousdiseases
hepatitis B 2 infectiousdiseases
infectious disease 1 infectiousdiseases
lymphocytic choriomeningitis 1 infectiousdiseases
meningitis 1 infectiousdiseases
smallpox 1 infectiousdiseases

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Select Disease Character Offset Disease Term Instance
AIDS 308 University of Montreal, Montreal, QC H2X 0A9, Canada; julia.niessl@umontreal.ca2Scripps Center for HIV/ AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), La Jolla, CA 92037, USAPublication date (epub):
AIDS 25340 (https://clinicaltrials.gov/ct2/show/NCT02968849?term=HVTN702&rank=1, accessed 27 May 2018). This study is based on the RV144 trial (ALVAC/ AIDS VAX), which demonstrated partial antibody-mediated protection [[126]]. Compared to unsuccessful HIV vaccine
diphtheria 23892 has shown great success in vaccinations against for example hepatitis A and B, human papilloma virus, diphtheria , or tetanus [[120]]. However, alum alone induces low Tfh responses when compared to other adjuvants
hepatitis A 23850 vaccinations (>80% of all licensed vaccines) and has shown great success in vaccinations against for example hepatitis A and B, human papilloma virus, diphtheria, or tetanus [[120]]. However, alum alone induces low Tfh responses
hepatitis B 1926 impact on prophylactic HIV vaccine research.1. IntroductionMost successful vaccines (e.g., against hepatitis B , yellow fever, and smallpox) work by inducing long-lasting neutralizing antibody responses that prevent
hepatitis B 30034 better induction of antibody responses or similar responses using a lower dose upon vaccination against hepatitis B , influenza or human papilloma virus compared to i.m [[131]]. In a NHP study, GC Tfh frequency and HIV-neutralizing
hepatitis C 17127 differentiation. Virus-specific Tfh expansion occurs in the context of other chronic viral infections such as hepatitis C in humans or lymphocytic choriomeningitis in mice [[91],[92]]. In addition to their accumulation, GC
infectious disease 36539 responses have been shown to be involved in the generation of protective antibody responses in various infectious disease s and after vaccination. Induction of more potent Tfh responses represents an interesting strategy for
lymphocytic choriomeningitis 17152 expansion occurs in the context of other chronic viral infections such as hepatitis C in humans or lymphocytic choriomeningitis in mice [[91],[92]]. In addition to their accumulation, GC Tfh cells showed phenotypic and functional
meningitis 17170 in the context of other chronic viral infections such as hepatitis C in humans or lymphocytic chorio meningitis in mice [[91],[92]]. In addition to their accumulation, GC Tfh cells showed phenotypic and functional
smallpox 1957 vaccine research.1. IntroductionMost successful vaccines (e.g., against hepatitis B, yellow fever, and smallpox ) work by inducing long-lasting neutralizing antibody responses that prevent infection of target cells
tetanus 23907 success in vaccinations against for example hepatitis A and B, human papilloma virus, diphtheria, or tetanus [[120]]. However, alum alone induces low Tfh responses when compared to other adjuvants or when alum
yellow fever 1939 prophylactic HIV vaccine research.1. IntroductionMost successful vaccines (e.g., against hepatitis B, yellow fever , and smallpox) work by inducing long-lasting neutralizing antibody responses that prevent infection

You must be authorized to submit a review.